Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15232


Purpose:

The combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.


Study summary:

Primary Objectives: - Phase I: To determine the safety, tolerability, and Phase II recommended dose of the combination of extended schedule TMZ and DAC. - Phase II: To determine the efficacy, as measured by overall response rate, of the combination of extended schedule TMZ and DAC given at the Phase II recommended dose to patients with metastatic melanoma. Secondary Objectives: - To determine pharmacokinetics of the combination of TMZ and DAC in patients with metastatic melanoma. - To determine, in peripheral blood mononuclear cells (PBMC) and tumor tissue, the pharmacodynamic effects of the combination of TMZ and DAC on promoter methylation and expression of selected genes and correlate these with response. - To determine the progression-free survival of patients treated with the combination of TMZ and DAC.


Criteria:

Inclusion Criteria: - Patients who have non-resectable Stage IIIB or stage IV metastatic melanoma that have progressed despite prior therapies. - Life expectancy of at least 12 weeks. - ECOG performance status of 0, 1 and 2. - ≥18 years of age. - Patients who have not received any other chemotherapeutic, biological or investigational agent within 28 days of study drug administration. - First line and active brain metastases (metastatic lesions to the brain that have been adequately treated with surgery and/or appropriate radiation therapy and that have documented stability for >4 weeks or >2 weeks if treated with stereotactic radiosurgery, remain eligible) Exclusion Criteria: - Any evidence of renal dysfunction (proteinuria, estimated creatinine clearance from serum creatinine test of <60 ml/min). - Impaired hepatic function (liver enzymes greater than twice the upper limit of normal or bilirubin > 2.0 except in patients with Gilbert's syndrome). - Prior treatment with alkylating agents (including TMZ and DTIC). - Active brain metastases (metastatic lesions to the brain that have been adequately treated with surgery and/or appropriate radiation therapy and that have documented stability for >4 weeks remain eligible). - Active infections or serious general medical conditions. - Female patients of child-bearing age who are not on adequate contraception, or are pregnant or breast-feeding.


NCT ID:

NCT00715793


Primary Contact:

Principal Investigator
Hussein Tawbi, MD
University of Pittsburgh


Backup Contact:

N/A


Location Contact:

Pittsburgh, Pennsylvania 15232
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 20, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.